KENUP-FOUNDATION
The European Investment Bank today launched the first ever scheme to strengthen local production of Active Pharmaceutical Ingredients in Africa and scale up drug manufacturing essential to improve public health. The EIB’s new EUR 50 million pharmaceutical investment initiative, initiated together with kENUP Foundation, will contribute to reducing dependency on drug imports and address medical supply chain weaknesses linked to COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005724/en/
The programme will improve availability of specialist drugs and tackle supply chain challenges that currently damage public health across Africa. This new initiative is aligned with World Health Organisation goals and the recently announced cooperation between the EIB and WHO to combat COVID-19 and strengthen health system resilience to better face future pandemics.
Scaling up pharmaceutical investment in Africa will help to protect millions of people from disease and disability and strengthen resilience to ongoing and future pandemics.
“Accelerating high-impact pharmaceutical investment across Africa is crucial to improve public health, address medical supply chain weaknesses and unlock long-term economic development. The European Investment Bank is pleased to launch the first ever-financing initiative to scale up local production of Active Pharmaceutical Ingredients in Africa. This scheme has been designed with African and global experts and builds on the EIB’s unique global technical experience and financing expertise supporting health and innovation investment.” said Thomas Östros, European Investment Bank Vice President.
“COVID-19 has highlighted how public health in Africa is vulnerable to global supply chains and dependent on international production. Increasing local specialist manufacturing of Active Pharmaceutical Ingredients will help to improve the public health of millions of Africans. This new initiative demonstrates how specialist pharmaceutical and financing expertise can create jobs and a better future for Africa.” said Dr Mariângela Batista Galvão Simão, World Health Organisation Assistant Director- General responsible for Access to Medicines and Health Products.
The Active Pharmaceutical Ingredients financing initiative was formally launched earlier today with participation of representatives from the European Investment Bank, World Health Organisation, EDCTP, Global Access in Action at Harvard Law School and kENUP Foundation. Kenyan-based non-profit APIFA (API for Africa) contributed their expertise throughout the process of establishing this financing facility and will act as a non-exclusive promotor to the facility.
“This is a timely facility that will transform the pharmaceutical manufacturing industry on the continent and thus enhance access to essential medicines for vulnerable populations. We call on all relevant stakeholders to now work together to support manufacturers in this transformation journey and ensure the long-term viability of this initiative”, says Gerald Macharia, a founding director of APIFA.
More information can be found at https://www.kenup.eu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005724/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 13:00:00 CET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET9.12.2025 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company’s collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the development of treatment models in TRD. Compass Pathways’ management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, as well as highlight the unmet need in post-traumatic stress disorder (PTSD) and provide details of the planned late-stage program for COMP360 in
Brands Poised for Growth: NIQ Identifies the Strategies Behind 2025’s Top Performing Innovations9.12.2025 12:00:00 CET | Press release
New analysis of 70,000+ manufacturers reveal the practices that double a brand’s chances of sustained sales growth. NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 4th Annual Innovation Vitality Report, revealing the strategies that are helping brands achieve multi-year growth from their innovation pipelines. Drawing on data from over 70,000 manufacturers across 130 categories, the report highlights the practices that double a company’s likelihood of expanding overall sales through top performing innovation. As retailers accelerate shelf refresh cycles and private label competition intensifies, brands are under increasing pressure to design innovations with staying power. NIQ’s findings show that top performing innovators consistently follow a repeatable formula, rooted in strong consumer-led ideas, early performance signals, and cross functional alignment, to build products that deliver long-term, incremental growth across global markets. Key Findin
Klarna Now Available on Apple Pay to Customers in France and Italy9.12.2025 11:49:00 CET | Press release
Klarna now live on Apple Pay in 8 countries — offering millions of consumers the ability to pay with installments when checking out online, in-app and in-person with Apple Pay Klarna, the global digital bank and flexible payments provider, has made its flexible payment products available when checking out on Apple Pay in France and Italy. Millions of eligible shoppers can now choose Klarna at checkout online and in-app using their iPhone and iPad, or in-store using their iPhone, and this innovative capability delivers even more convenience, control, and transparency to even more customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209410835/en/ The continued expansion follows strong consumer adoption and momentum in Denmark, Spain, Sweden, the U.S., UK and Canada, where Klarna’s flexible payment options have become a popular way to pay with Apple Pay. With today’s launch, consumers across eight major markets can now
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for Cutting-Edge Semiconductors9.12.2025 11:12:00 CET | Press release
- Supports 1.4nm Generation Semiconductors, Reduces Manufacturing Costs and Energy Consumption - Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/ Template for nanoimprint Background and Aims In line with the shift to more sophisticated devices seen in recent years, demands have emerged for even greater miniaturization in cutting-edge semiconductors, leading to advances in Extreme Ultra-Violet (EUV) lithography-based production. EUV lithography, however, requires substantial capital investment, energy consumption, and operating costs in building production l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom